- Home/
- IPO
2.40x
subscribed
Molbio Diagnostics IPO
Hospital & Healthcare Services
open
2.40x
subscribed
₹13,824Min. investment
Molbio Diagnostics Limited IPO Details
Issue size
₹940Cr
IPO type
Mainboard
Market Cap
₹9,299CrLower than sector avg
Price range
₹768 – ₹807
Listing ExchangeBSE, NSE
RevenueApr 2025 - Mar 2026
₹1,445CrHigher than sector avg
Lot size
18 shares
Red Herring Prospectus
Read
Growth rate3Y CAGR
31.46%
SectorHospital & Healthcare Services
Price range₹768 – ₹807
IPO type
Regular
Lot size18 shares
Issue size₹940Cr
Red Herring Prospectus
Read
Market Cap
₹9,299CrLower than sector avg
RevenueApr 2025 - Mar 2026
₹1,445CrHigher than sector avg
Growth rate3Y CAGR
31.46%
Molbio Diagnostics Limited IPO Overview
Molbio Diagnostics IPO date
Molbio Diagnostics IPO will open for subscription on August 10, 2026, and the closing date for the IPO is August 12, 2026. After this, investors are expected to be updated about the allotment status on August 13, 2026.
Investors who have been allotted shares can expect them to be credited to their demat account on August 14, 2026. The shares will be listed on the NSE and the BSE on Monday, August 17, 2026.
Molbio Diagnostics IPO price band
The IPO includes fresh issues and an offer for Sale. The IPO price band has been set between ₹ 768 and ₹ 807 per share. Interested investors can choose a price within this band to apply for the IPO.
The IPO is a book-building issue, comprising a fresh issue of ₹200 crore and an offer for sale of ₹740 crore. Molbio Diagnostics IPO listing price will be determined on August 17, 2026. The listing price is the price at which a company’s shares debut on the stock exchanges.
Molbio Diagnostics IPO lot size
Molbio Diagnostics IPO details have been declared. The minimum lot size for an application is 18 shares, and the investor would have to apply for a minimum of 1 lot. Meanwhile, the IPO issue size is approximately ₹940 crore.
Checklist
Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial
health at a glance and identify quality investment opportunities easily
Compare
Companies in this sector
Apollo Hospitals Enterprise Ltd
Max Healthcare Institute Ltd
Fortis Healthcare LtdObjectives
Capital expenditure
52.70%
Capex for plant and machinery
36.10%
General corporate purposes
11.10%
Strength and Weakness
Strong global presence
The company has sold over 12,500 devices in 90+ countries as of March 31, 2026 and plans to scale up further in Africa, Southeast Asia, Latin America and eventually break into the US and European markets.
Wide disease testing platform
Truenat can support testing for 30 diseases using 43 assays including TB, COVID-19, HIV, Hepatitis B & C and HPV. The same device can be used for several tests.
Strong R&D driving innovation
The company spent 6.05% of revenue on R&D in FY26 and has 153 R&D professionals including 136 scientists. In addition, it has built an extensive intellectual property portfolio of 207 patents granted worldwide to support future product launches.
Proprietary platform with strong global validation
The company has developed a proprietary portable PCR platform, Truenat, which took ~13 years of R&D to develop. It is the only rapid molecular test for TB developed in India and one of only two in the world to have received WHO endorsement for the initial diagnosis of TB and detection of resistance to Rifampicin.
Integrated healthcare solutions
The company has grown from molecular diagnostics to end-to-end screening and diagnostic solutions with the acquisitions of Prognosys and OptraScan.
About Molbio Diagnostics Limited
Molbio Diagnostics is an innovation-driven point-of-care (POC) diagnostics company that develops rapid, accurate and affordable diagnostic solutions for infectious as well as non-communicable diseases. Its flagship 'Truenat' platform is a portable, battery-operated PCR testing system that can be used even in resource-limited settings. As of March 31, 2026, the Truenat platform was protected by patents in more than 100 countries for diagnosing multiple infectious and non-communicable diseases.
As of March 31, 2026, the company offered molecular diagnostic solutions for 30 diseases through 43 assays. Its product portfolio covers major diseases such as tuberculosis (TB), COVID, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) and Human Papillomavirus (HPV).
The Truenat platform consists of two portable devices. The Trueprep system performs fully automated nucleic acid extraction, while the Truelab analyser carries out real-time PCR testing. The analyser is available in three variants: UnoDx, Duo and Quattro, which can process one, two and four samples simultaneously, respectively. As of March 31, 2026, the company had supplied more than 12,500 devices across over 90 countries, serving public health programmes, diagnostic laboratories and both private and public hospitals.
The company sold 2,524 devices in FY26, compared with 2,180 devices in FY25 and 2,011 devices in FY24. Out of the 2,524 devices sold during FY26, 2,184 devices were sold in India, while 340 devices were exported to international markets. Sales of Truenat test kits also witnessed strong growth, increasing to 1.76 crore in FY26 from 1.22 crore in FY25 and 88 lakhs in FY24. Similarly, out of 1.76 crore test kits sold during FY26, 1.62 crore were sold in India, and 13.6 lakhs were supplied to overseas markets.
Molbio Diagnostics operates six manufacturing facilities across India. Four facilities are operated directly by the company, including two in Goa, one in Bengaluru, Karnataka, and one in Visakhapatnam, Andhra Pradesh. In addition, its subsidiary Prognosys Medical Systems Private Limited and OptraScan India Private Limited operate facilities in Bengaluru and Pune, respectively. As of March 31, 2026, the company had an installed manufacturing capacity of 5,400 devices per annum and 39,000,000 Truenat test kits per annum. Capacity utilisation stood at 42.30% for devices and 58.25% for test kits in FY26.
In March 2023, the company acquired a 65.47% stake in Prognosys Medical Systems Private Limited and increased it further to 70% in April 2026. This new company offers digital imaging solutions, including radiology products under the "ProRad" brand. Further, in October 2024, the company entered into a stock purchase agreement to acquire a 60% stake in US-based OptraScan INC, which provides digital pathology solutions. The company has partnered with several organisations including Xcyton Diagnostics, Stellar Diagnostics, Testi Technologies, HealSeq, UE Lifesciences and HealSeq to broaden its diagnostic capabilities and accelerate product development.
The company's business continues to be driven by recurring sales of test kits. During FY26, revenue from test kits stood at ₹1,034.8 crore, contributing 73.9% of revenue from contracts with customers for finished goods, and revenue from device sales was ₹203.2 crore, accounting for 14.5% of revenue.
India is the largest market for the company, contributing 90.3% of FY26 revenue, while international markets accounted for 9.6% of revenue. Government bodies and international aid agencies continued to be the company's key customer segment, contributing 84.5%, 87.8% and 91.6% of revenue from contracts with customers for finished goods during FY26, FY25 and FY24, respectively.
The global point of care testing (POCT) market is valued at $29.3 billion (₹2,58,860 crore) and is projected to grow at a CAGR of 17.9% from 2025 to 2030 to reach $67.1 billion (₹ 5,92,820 crore) by 2030. Infectious diseases remain among the greatest challenges to health care globally. In 2023, they accounted for around 31.0% (1.94 crore) of all deaths globally. Diseases such as tuberculosis, hepatitis and HPV together killed almost 15 lakh people worldwide that’s more than 4,100 deaths each day.
The global shift from conventional smear-based TB testing to molecular diagnostics still represents a huge opportunity for growth. Around 15 to 20 crore smear tests are carried out each year worldwide, and many of these are expected to move to molecular testing over time. The top 30 countries with the highest TB burden account for 87% of the global tuberculosis burden. The top 8 countries account for ~2/3rd of the globally reported 1.07 crore new active TB cases in 2024.
The company’s Truenat TB platform is also the only rapid molecular TB test developed by an Indian company and one of only two such tests globally to receive WHO endorsement for the initial diagnosis of tuberculosis and detection of rifampicin resistance, giving the company a strong competitive advantage. It plans to further strengthen its product portfolio by developing 34 additional assays covering 22 diseases. These new assays are expected to enhance the utility of the Truenat platform and expand its addressable market. Also, the company aims to increase exports, particularly in regions where it already has a presence, such as Africa and Southeast Asia. In addition, it is working towards entering the United States and European Union markets and is in the process of registering the Truenat platform in several new countries.
Now, Molbio Diagnostics is launching its initial public offering (IPO), which consists of a fresh issue of ₹200 crore and an offer for sale of ₹740 crore. The total issue size of the IPO is ₹940 crore, and its shares will be listed on the NSE and BSE.
How to pre-apply for Molbio Diagnostics IPO?
You can pre-apply for Molbio Diagnostics IPO on Upstox. The pre-application for this IPO, which means the pre-apply open date, usually begins a day before the IPO opens for subscription.
Follow these steps to pre-apply for the IPO:
- Login to your Upstox account, using your six-digit PIN
- After successfully logging in, click on ‘Discover’
- On the Discover tab, you will find the ‘Invest in IPO’ section
- Under the Invest in IPO section, look for the ‘Molbio Diagnostics IPO’ tab and click on it
- Now fill in all the required information, like ‘bid price’ and ‘lot size’
- Confirm and click on ‘Pre-Apply’
- Accept the mandate on your UPI app
How to apply for Molbio Diagnostics IPO?
If you are interested in this investment opportunity but unsure how to apply for Molbio Diagnostics IPO, here are the steps that you need to follow.
When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for Molbio Diagnostics IPO on Upstox:
- Log in to your Upstox account, using your six-digit PIN
- After logging in, click on ‘Discover’
- On the ‘Discover’ tab, you will find the ‘Invest in IPO’ section
- Under the Invest in IPO section, look for the ‘Molbio Diagnostics IPO’ tab and click on it
- Now fill in all the required information, like ‘bid price’ and ‘lot size’
- Confirm and click on ‘Apply’
- Accept the mandate on your UPI app
**How to check the Molbio Diagnostics IPO allotment status? **
When the allotment process is completed, you can check the status of your application on the Upstox app. Share allotment is generally completed on the next working day after an IPO closes.
Here’s a step-by-step guide on how to check the Molbio Diagnostics IPO allotment status:
- Login to your Upstox account, using your six-digit PIN
- After logging in, click on ‘Discover’
- On the ‘Discover’ page, you will find the ‘Invest in IPO’ section
- Under the Invest in IPO section, you will find the ‘View all’ option
- Once you click on ‘View all’, you will be directed to the ‘IPO’ tab
- In the ‘IPO’ tab, click on ‘My applications’
- In ‘My applications’, under the History section, your Molbio Diagnostics IPO allotment status will be mentioned.
IPO Analysis
IPO REVIEW
Molbio Diagnostics IPO
Should you apply?
View Video
Molbio Diagnostics IPO Subscription Status
Latest News on Molbio Diagnostics IPO
Molbio Diagnostics IPO comprises a fresh issuance of equity shares aggregating up to ₹200 crore and an offer-for-sale (OFS) component of up to 1.25 crore shares by existing shareholders.
2 min read
The ₹939.70 crore Molbio Diagnostics IPO is a mix of fresh issuance of shares totalling ₹200 crore and an offer for sale (OFS) of ₹739.70 crore by promoters and existing shareholders.
3 min read
Frequently asked questions
How to invest in the Molbio Diagnostics IPO ?
Investors can apply for the Molbio Diagnostics IPO through their Demat account via the stock exchange or through their broker.
What is the issue size of Molbio Diagnostics IPO ?
The issue size of the Molbio Diagnostics IPO is 940 Cr.
What is 'pre-apply' for Molbio Diagnostics IPO ?
Pre-applying for an IPO allows you to submit your application before the official subscription period begins.
Which exchanges will Molbio Diagnostics IPO shares list on?
The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.
Bidding closes on 12 Aug 2026, 5:00 PM